March 16 (Reuters) -
* MODERNA ANNOUNCES FIRST PARTICIPANTS DOSED IN PHASE 2/3 STUDY OF COVID-19 VACCINE CANDIDATE IN PEDIATRIC POPULATION
* MODERNA - STUDY WILL EVALUATE SAFETY, TOLERABILITY & EFFECTIVENESS OF TWO DOSES OF MRNA-1273 IN PEDIATRIC PARTICIPANTS GIVEN 28 DAYS APART
* MODERNA - PHASE 2/3 MRNA-1273 STUDY EXPECTED TO ENROLL 6,750 HEALTHY PEDIATRIC PARTICIPANTS WITH AGES 6 MONTHS TO LESS THAN 12 YEARS IN U.S. & CANADA Further company coverage: MRNA.O